ADHD - FDA expands indication for ADDERALL XR® (CII) confirming safety and efficacy in adolescents
Sat, 23 Jul 2005 10:00 PM EST
... Shire Pharmaceuticals Group plc announced today that the US Food and Drug Administration (FDA) has approved ADDERALL XR® (mixed salts of a single-entity amphetamine product) as a once-daily treatment for adolescents aged 13 to 17 with attention deficit hyperactivity disorder (ADHD)... click link for more info. ...
Related Topics
- Amphetamine and Dextroamphetamine ER
- Amphetamine and Dextroamphetamine
- Drug Safety
- Food Safety
- Fire Safety
- Child Safety
- Sports Safety
- Electrical Safety
- Workplace Safety & Health
- Safety (General)
- Traffic Safety
- Safety
- Machine Safety
- Chemical Safety
- Vehicle Safety
- Consumer Product Safety
- Methylphenidate ER
- Dextroamphetamine
- Safety Issues
- Motor Vehicle Safety

Not Signed In -


